LeadIQ logo
Learn more at LeadIQ.com

Insights

Strategic Pipeline Immunome is a clinical-stage oncology company with a diverse ADC portfolio including varegacestat for desmoid tumors and multiple clinical-stage ADC programs (IM-1021, IM-1617, IM-3050). This indicates potential collaboration or licensing opportunities around immune-oncology targets and novel payloads.

Recent Milestones Recent NDA submission for varegacestat and first patient dosing for IM-1617 signal near-term value events. Capitalize on near-term interest from investors and potential partners seeking late-stage readouts or first-in-class assets.

Strategic Partnerships Existing collaboration with Infinimmune to discover antibody drugs suggests openness to co-development or out-licensing, presenting opportunities for BD partners to access Immunome’s ADC platform and pipeline expansions.

Investor & Outreach Active engagement with major investor conferences (Goldman Sachs Healthcare Conference, JP Morgan Healthcare Conference) indicates a window to align sales messaging with potential strategic investors, pharma scouts, or large biotech buyers evaluating strategic assets.

Scale & Capabilities Large funding position (nearly $1B) combined with global biopharma-facing capabilities and a leadership team with deep ADC experience. This supports discussions around co-development, milestone-driven deals, and access to Immunome’s development and regulatory readiness.

Similar companies to Immunome, Inc.

Immunome, Inc. Tech Stack

Immunome, Inc. uses 8 technology products and services including Alteryx, Microsoft SharePoint, Snowflake, and more. Explore Immunome, Inc.'s tech stack below.

Media & News

Immunome, Inc.'s Email Address Formats

Immunome, Inc. uses at least 3 email formats:
Immunome, Inc. Email FormatsExamplePercentage
FLast@immunome.comJDoe@immunome.com
97%
First.Last@immunome.comJohn.Doe@immunome.com
2%
FiLast@immunome.comJoDoe@immunome.com
1%

Frequently Asked Questions

What is Immunome, Inc.'s phone number?

Minus sign iconPlus sign icon You can contact Immunome, Inc.'s main corporate office by phone at
+1-610-321-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Immunome, Inc.'s stock symbol?

Minus sign iconPlus sign iconImmunome, Inc. is a publicly traded company; the company's stock symbol is IMNM.

What is Immunome, Inc.'s official website and social media links?

Minus sign iconPlus sign iconImmunome, Inc.'s official website is immunome.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Immunome, Inc. generate?

Minus sign iconPlus sign icon As of October 2026, Immunome, Inc.'s annual revenue is estimated to be $1M - $10M.

What is Immunome, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign iconImmunome, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Immunome, Inc. have currently?

Minus sign iconPlus sign iconAs of October 2026, Immunome, Inc. has approximately 279 employees across 3 continents, including North America, Asia and Europe. Key team members include Vp Regulatory Affairs, Al102: C. N., Vp Clinical Development, Al102: J. Y. and Chairman Of The Board-Board: M. R. Explore Immunome, Inc.'s employee directory with LeadIQ.

What industry does Immunome, Inc. belong to?

Minus sign iconPlus sign iconImmunome, Inc. operates in the Biotechnology Research industry.

What technology does Immunome, Inc. use?

Minus sign iconPlus sign iconImmunome, Inc.'s tech stack includes Alteryx, Microsoft SharePoint, Snowflake, Shopify, ServiceNow, WP Engine, SAP Concur and Zoom.

What is Immunome, Inc.'s email format?

Minus sign iconPlus sign iconImmunome, Inc.'s email format typically follows the pattern of FLast@immunome.com. Find more Immunome, Inc. email formats with LeadIQ.

How much funding has Immunome, Inc. raised to date?

Minus sign iconPlus sign icon As of October 2026, Immunome, Inc. has raised $999M in funding. The last funding round occurred on Dec 16, 2025 for $150M.

When was Immunome, Inc. founded?

Minus sign iconPlus sign iconImmunome, Inc. was founded in 2016.
Immunome, Inc. logo

Immunome, Inc.

Biotechnology ResearchWashington, United States201-500 Employees

Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. Based in Bothell, Washington, the company aims to deliver first-in-class and best-in-class treatments that improve outcomes for patients with solid tumors and desmoid tumors. Leadership includes veterans who helped design, develop, and commercialize targeted cancer therapies, including antibody-drug conjugates. Its pipeline features varegacestat (AL102), a gamma secretase inhibitor in Phase 3 for desmoid tumors, for which an NDA was submitted to the FDA in 2026; IM-1021, a ROR1-targeted ADC in Phase 1; and IM-3050, a FAP-targeted radioligand that has recently received IND clearance. The company is advancing additional preclinical ADCs—IM-1617, IM-1335, and IM-1340—for undisclosed targets expressed in multiple solid tumors.

Section iconCompany Overview

Phone number
+1-610-321-****
Website
immunome.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
IMNM
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
201-500

Section iconMedia & News

Section iconFunding & Financials

  • $999M

    Immunome, Inc. has raised a total of $999M of funding over 22 rounds. Their latest funding round was raised on Dec 16, 2025 in the amount of $150M as a Post IPO Equity.

  • $1M - $10M

    Immunome, Inc.'s revenue is estimated to be in the range of $1M - $10M

Company Leadership

  • Vp Regulatory Affairs, Al102 at Immunome, Inc.
    C. N.
    Vp Regulatory Affairs, Al102
    Mobile Phone
  • Vp Clinical Development, Al102 at Immunome, Inc.
    J. Y.
    Vp Clinical Development, Al102
    Mobile Phone
  • Chairman Of The Board-Board at Immunome, Inc.
    M. R.
    Chairman Of The Board-Board
    Mobile Phone
  • Co Founder at Immunome, Inc.
    P. B.
    Co Founder
    Mobile Phone
  • Senior Vice President at Immunome, Inc.
    D. C.
    Senior Vice President
    Mobile Phone

Employee Directory

  • Executive Director Of Quality Assurance, Al102 at Immunome, Inc.
    S. I.
    Executive Director Of Quality Assurance, Al102
    Mobile Phone
  • Director, Market Insights at Immunome, Inc.
    B. A.
    Director, Market Insights
    Mobile Phone
  • Senior Director Of Statistical Programming at Immunome, Inc.
    M. M.
    Senior Director Of Statistical Programming
    Mobile Phone
  • Director, Development Quality Assurance at Immunome, Inc.
    S. K.
    Director, Development Quality Assurance
    Mobile Phone
  • Director Of Information Technology at Immunome, Inc.
    D. K.
    Director Of Information Technology
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.